SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

NanoViricides Says NV-387 Ebola Trial Advancing to Phase II Second Part

NanoViricides says its Phase II clinical trial of NV-387 oral gummies is advancing to the second part.

NNVC

Story updates

01:17:20 PM UTC
SquawkNews
NanoViricides said its NV-387 Oral Gummies Ebola Phase IIA trial in DRC is progressing and is expected to advance into Phase IIB upon completion of the IIA part, which targets ~20 patients with a 28—day survival endpoint.Material DetailsContext by AI AnalystThis is an early-to-mid clinical update r…

Related stories